Supplementary figures 1-6 from CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation

https://doi.org/10.1158/0008-5472.22408770

figure

posted on 2023-03-30, 23:43 authored by Yuan Liu, Elianna B. Amin, Marty W. Mayo, Neel P. Chudgar, Peter R. Bucciarelli, Kyuichi Kadota, Prasad S. Adusumilli, David R. Jones

<p>S1: TNF-induced phosphorylation of BRMS1 is independent of NF-κB. S2: CK2α' endogenously interacts with BRMS1. S3: 14-3-3ε interacts with BRMS1. S4: Activation of CK2α' enhances the invasion potential of NSCLC cells. S5: Activation of CK2α' is incapable of affecting primary tumor growth. S6: CK2α' kinase activity is increased in tumors with lymph nodal metastasis.</p>

Funding

NIH

NCI

History

Related Materials

1.
DOI - Is supplement to CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation

ARTICLE ABSTRACT

Breast cancer metastasis suppressor 1 (BRMS1) is decreased in non–small cell lung cancer (NSCLC) and other solid tumors, and its loss correlates with increased metastases. We show that BRMS1 is posttranslationally regulated by TNF-induced casein kinase 2 catalytic subunit (CK2α') phosphorylation of nuclear BRMS1 on serine 30 (S30), resulting in 14-3-3ϵ–mediated nuclear exportation, increased BRMS1 cytosolic expression, and ubiquitin-proteasome–induced BRMS1 degradation. Using our in vivo orthotopic mouse model of lung cancer metastases, we found that mutation of S30 in BRMS1 or the use of the CK2-specific small-molecule inhibitor CX4945 abrogates CK2α'-induced cell migration and invasion and decreases NSCLC metastasis by 60-fold. Analysis of 160 human NSCLC specimens confirmed that tumor CK2α' and cytoplasmic BRMS1 expression levels are associated with increased tumor recurrence, metastatic foci, and reduced disease-free survival. Collectively, we identify a therapeutically exploitable posttranslational mechanism by which CK2α-mediated degradation of BRMS1 promotes metastases in lung cancer. Cancer Res; 76(9); 2675–86. ©2016 AACR.